Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (NASDAQ: NTLA) announced a public offering of $75 million in common stock with a 30-day option for underwriters to purchase an additional 15%. The offering is subject to market conditions, and all shares will be sold by Intellia. Goldman Sachs, Jefferies, and SVB Leerink are managing the offer. The shares are available under a shelf registration statement filed with the SEC. This announcement reflects Intellia's ongoing commitment to funding its genome editing technology using CRISPR/Cas9.
Intellia Therapeutics (NASDAQ: NTLA) showcased its innovative CRISPR/Cas9 technology during the ASGCT Annual Meeting, presenting promising data on NTLA-5001 for acute myeloid leukemia (AML) and NTLA-2002 for hereditary angioedema (HAE). The proprietary process for NTLA-5001 enables multiple gene edits in T cells, leading to enhanced therapeutic potential. Data revealed >98% efficiency in gene editing with minimal adverse translocations. NTLA-2002 demonstrated a sustained 90% reduction in kallikrein activity, indicating significant efficacy in reducing HAE attack rates. IND submissions for both drug candidates are anticipated in 2021.
Intellia Therapeutics (NASDAQ: NTLA) announced key updates in its pipeline for Q1 2020, focusing on its CRISPR/Cas9 technology. The company plans to submit INDs for its lead therapies: NTLA-2001 for transthyretin amyloidosis by mid-2020, NTLA-5001 for acute myeloid leukemia in 1H 2021, and NTLA-2002 for hereditary angioedema in 2H 2021. Intellia ended the quarter with a cash position of $250 million, expecting a runway through the end of 2021. However, research and development expenses rose, leading to a net loss of $31.8 million compared to $21.9 million in Q1 2019.
Summary not available.
Summary not available.
Summary not available.